NCT06723535View on ClinicalTrials.gov

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 7, 2024

Primary Completion Date

September 16, 2025

Study Completion Date

September 19, 2025

Conditions
Kidney Failure, ChronicHealthy VolunteersRenal Impairment
Interventions
DRUG

BMS-986278

Specified dose on specified days

Trial Locations (4)

33172

Local Institution - 0003, Miami

33147-4040

Local Institution - 0002, Miami

32808-7820

Local Institution - 0004, Orlando

32809-3017

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06723535 - A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis | Biotech Hunter | Biotech Hunter